O Nevo Displásico

Susana Brás; Ana Isabel Gouveia; Ana Isabel Teixeira; André Laureano Oliveira; Luis Miguel Soares Almeida

doi:10.29021/spdv.74.3.592

Susana Brás Interna do Internato Complementar de Dermatovenereologia/Resident, Dermatology and Venereology, Serviço de Dermatovenereologia, Centro Hospitalar Lisboa Central, Lisboa, Portugal
Ana Isabel Gouveia Interna do Internato Complementar de Dermatovenereologia/Resident, Dermatology and Venereology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
Ana Isabel Teixeira Interna do Internato Complementar de Dermatovenereologia/Resident, Dermatology and Venereology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
André Laureano Oliveira Assistente Hospitalar/Consultant of Dermatology, Unidade de Dermatologia, British Hospital, Lisboa, Portugal
Luis Miguel Soares Almeida Assistente Hospitalar Graduado de Dermatovenereologia Senior Graduate Assistant in Dermatology; Professor Associado/ Associated Professor, Faculdade de Medicina de Lisboa, Unidade de Investigação em Dermatologia, IMM Universidade de Lisboa, Serviço de Dermatovenereologia, Hospital de Santa Maria; Centro Hospitalar Lisboa Norte, Portugal

DOI: https://doi.org/10.29021/spdv.74.3.592

Palavras-chave: Lesões Pré-Cancerosas, Melanoma, Neoplasias da Pele, Síndrome do Nevo Displásico

Resumo

O nevo melanocítico displásico é uma entidade controversa. Os autores realizaram uma revisão da literatura com o objectivo de tentar esclarecer o que é um nevo displásico, quais os critérios actuais para o seu diagnóstico, qual a sua relação com o risco de melanoma e como abordar o doente com história de nevos displásicos.

Downloads

Não há dados estatísticos.

Referências

Rosendahl CO, Grant-Kels JM, Que SKT. Dysplastic nevus: Fact and fiction. J Am Acad Dermatol. 2015:1-

Dediol I, Bulat V, Zivković MV, Marković BM, Situm M. Dysplastic nevus--risk factor or disguise for melanoma. Coll Antropol. 2011;35 Suppl 2:311-3.

Shapiro M, Chren MM, Levy RM, Elder DE, LeBoit PE, Mihm MC Jr, et al. Variability in nomenclature used for

nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and

dermatopathologists. J Cutan Pathol. 2004;31:523-30.

Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27-29,1992. Consens Statement. 1992;10:1-25.

Davis N. William Norris, MD: a pioneer in the study of melanoma. Med J Aust. 1980;26:52-4.

Cawley EP, Kruse WT, Pinkus HK. Genetic aspects of malignant melanoma. AMA Arch Derm Syphilol.

;65:440-50.

Munro DD. Multiple active junctional naevi with family history of malignant melanoma. Proc R Soc Med

;67:594-5.

Clark WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas

from heritable melanocytic lesions. “The B-K mole syndrome”. Arch Dermatol. 1978;114:732-8.

Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet.

;15:352-6.

Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH. Dysplastic nevus syndrome: a phenotypic

association of sporadic cutaneous melanoma. Cancer. 1980;46:1787-94.

Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41:45-60.

Xiong MY, Rabkin MS, Piepkorn MW, Barnhill RL, Argenyi Z, Erickson L, et al. Diameter of dysplastic nevi

is a more robust biomarker of increased melanoma risk than degree of histologic dysplasia: A case-control

study. J Am Acad Dermatol. 2014;71:1257-8.e4.

Garbe C, Bauer J. Melanoma. In: Bolognia JL, Schaffer JV, Jorizzo JL, editors. Dermatology. 3rd ed. London: Mosby.; 2006.p1885-914.

Tucker M, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, et al. A natural history of melanomas and dysplastic nevi: An atlas of lesions in melanoma-prone families. Cancer. 2002;94(:3192-209.

Ackerman AB. What naevus is dysplastic , a syndrome and the commonest precursor of malignant melanoma ? A riddle and an answer. Histopathology. 1988;13:241-56.

Ackerman AB, Cerroni L, Kerl H. Pitfalls in histopathologic diagnosis of malignant melanoma. Philadelphia: Lea & Febiger; 1994.

Ackerman AB, Magana-Garcia M. Naming acquired melanocytic nevi. Common and dysplastic, normal and

atypical, Unna, Miescher, Spitz and Clark? Am J Dermatopathol. 1992;14:447-53.

Kittler H, Tschandl P. Dysplastic Nevus. Dermatol Clin. 2013;31:579-88.

Hurwitz RM. Consequences of a diagnosis of dysplastic nevus. J Cutan Pathol. 2014;41:407.

Lozeau DF, Farber MJ, Lee JB. A nongrading histologic approach to Clark (dysplastic) nevi: A potential

to decrease the excision rate. J Am Dermatology. 2015;74):68-74.

Elder DE, Chb MB. Point: What’s in a name? J Am Dermatology. 2015;73:513-4.

Kossard S, Commens C, Symons M, Doyle J. Lentinginous dysplastic naevi in the elderly: a potential precursor for malignant melanoma. Australas J Dermatol. 1991;32:27-37.

Weedon D. Lentiginous melanoma. J Cutan Pathol. 2009;36:1232.

Kossard S. Atypical lentiginous junctional naevi of the elderly and melanoma. Australas J Dermatol.

;43:93-101.

Davis T, Zembowicz A. Histological evolution of lentiginous melanoma: A report of five new cases. J Cutan

Pathol. 2007;34:296-300.

Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang ML, et al. Roads to melanoma: Key

pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta -

Mol Cell Res. 2016;1863:770-84.

Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations

in nevi. Nat Genet. 2003;33:19-20.

Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma

from precursor lesions. N Englg J Med.2015;373:1926-36.

Vogelstein B, Kinzler KW. The path to cancer — three strikes and you’re out. N Englg J Med. 2015;373:1893-5.

Yeh I. Recent advances in molecular genetics of melanoma progression: implications for diagnosis and

treatment. F1000Res. 2016;5:1-8.

Hofmann- R, Marghoob AA, Service D, Sloan M, Cancer K, Zalaudek I. Large acquired nevus or dysplastic

nevus what ’ s in the name of a nevus cq JAMA Dermatol. 2016;152:623-4.

Duffy K, Grossman D. The dysplastic nevus: From historical perspective to management in the modern era: Part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol. 2012;67:1.e1-1.e16.

Tucker MA. Atypical melanocitic nevi. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DL, Wolff K,

editors. Fitzpatrick’s Dermatology in General Medicine 7 ed. New York: McGraw-Hill; 2008. p.1161-9.

Hansson J, Bergenmar M, Hofer PÅ, Lundell G, Månsson-Brahme E, Ringborg U, et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: Results of a Swedish preventive program. J Clin Oncol. 2007;25:2819-24.

Friedman RJ, Farber MJ, Warycha M, Papathasis N, Miller MK, Heilman ER. The “dysplastic” nevus. Clin Dermatol. 2009;27:103-15.

Carrera C, Marchetti MA, Dusza SW, Argenziano G, Braun RP, Halpern AC, et al. Validity and reliability of

dermoscopic criteria used to differentiate nevi from melanoma. JAMA Dermatol. 2016;10022:1-9.

Rezze GG, Leon A, Duprat J. Nevo displásico (nevo atípico). An Bras Dermatol. 2010;85:863-71.

Rezze GG, Leon A, Duprat J. Errata Referente ao artigo publicado na revista 85(6). An Bras Dermatol. 2011;86:182.

Malvehy J, Puig S, Braun R, Marghoob AA, Kopf AW. Manual de Dermatoscopía. Barcelona: BNC Art Directe; 2006.

Annessi G, Bono R, Sampogna F, Faraggiana T. Sensitivity, specificity, and diagnostic accuracy of three

dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light

brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol. 2007;56:759-67.

Hofmann-Wellenhof R, Blum A, Wolf IH, Piccolo D, Kerl H, Garbe C, et al. Dermoscopic classification of

atypical melanocytic nevi (Clark nevi). Arch Dermatol. 2001;137:1575-80.

Zalaudek I, Schmid K, Marghoob AA, Scope A, Manzo M, Moscarella E, et al. Frequency of dermoscopic

nevus subtypes by age and body site. Arch Dermatol. 2011;147:663-70.

Zalaudek I, Docimo G, Argenziano G. Using dermoscopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol. 2009;145:816-26.

Scope A, Marchetti M, Marghoob A, Dusza SW, Geller AC, Satagopan JM, et al. The study of nevi in children: Principles learned and implications for melanoma diagnosis. J Am Acad Dermatol. 2016 (in press).

Gamo R, Malvehy J, Puig S, Fuentes ME, Naz E, Gómez de la Fuente E, et al. Dermoscopic features of melanocytic nevi in seven different anatomical locations in patients with atypical nevi syndrome. Dermatol Surg. 2013;39:864-71.

Ackerman AB, Mihara I. Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome,

and the relation between dysplastic nevi and malignant melanomas. Hum Pathol. 1985;16:87-91.

Clemente C, Cochran AJ, Elder DE, Levene A, MacKie RM, Mihm MC, et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol. 1991;22:313-9.

Duncan LM, Berwick M, Bruijn J, Byers HR, Mihm MC, Barnhill RL. Histopathologic recognition and grading

of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol. 1993;100:318S-21S.

Weinstock M a, Barnhill RL, Rhodes R, Brodsky GL. Reliability of the histopathologic diagnosis of melanocytic dysplasia. The Dysplastic Nevus Panel. Arch Dermatol. 1997;133:953-8.

Arumi-Uria M, McNutt NS, Finnerty B. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol. 2003;16:764-71.

Cockerell CJ. Counterpoint: The “dysplastic” nevus. J Am Acad Dermatol. 2015;73:515-7.

Duffy K, Grossman D. The dysplastic nevus: From historical perspective to management in the modern era: Part II. Molecular aspects and clinical management. J Am Acad Dermatol. 2012;67:19.e1-19.e12.

Massi G. Melanocytic nevi simulant of melanoma with medicolegal relevance. Virchows Arch. 2007;451:623-47.

Hurwitz R, Tavel M. The mythical concept and untoward consequences of a diagnosis of dysplastic nevus: an overdue tribute to A. Bernard Ackerman, MD. Dermatol Pract Concept. 2015;5:31-4.

Elder DE. Precursors to melanoma and their mimics: nevi of special sites. Mod Pathol. 2006;19 Suppl 2:S4-S20.

North JP, Garrido MC, Kolaitis N, Leboit PE, McCalmont TH, Bastian BC. Fluorescence in situ hybridization as an ancillary tool in the diagnosis of ambiguous melanocytic neoplasms: a review of 804 cases. Am J Surg

Pathol. 2014;38:824-31.

March J, Hand M, Grossman D. Practical application of new technologies for melanoma diagnosis: Part

I. Noninvasive approaches. J Am Acad Dermatol. 2015;72:929-41.

Tripp JM, Kopf AW, Marghoob AA, Bart RS. Management of dysplastic nevi: A survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol. 2002;46:674-82.

Kim C, Swetter S, Curiel-Lewandrowski C, Grichnik JM, Grossman D, Halpern AC, et al. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/

dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA Dermatol. 2015;151:212-8.

Hocker TL, Alikhan A, Comfere NI, Peters MS. Favorable long-term outcomes in patients with histologically

dysplastic nevi that approach a specimen border. J Am Dermatol. 2012;68:545-51.

Goodson AG, Florell SR, Boucher KM, Grossman D. Low rates of clinical recurrence after biopsy of benign

to moderately dysplastic melanocytic nevi. J Am Acad Dermatol. 2010;62:591-6.

Gadeliya Goodson A, Grossman D. Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol. 2009;60:719-35.

Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: Update on syndromes and

management Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad.Dermatol.

;74:411-20.

Watts CG, Madronio CM, Morton RL, Goumas C, Armstrong BK, Curtin A, et al. Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A population-based study in New South Wales, Australia. Australas J Dermatol. 2016(inpress).